このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

慢性腎臓病患者における高カリウム含有量の健康的な植物ベース食と、制限カリウム含有量の健康的な植物ベース食の安全性比較:パイロット研究 (SAFE-K)

2026年9月29日 更新者:Carla Maria Avesani、Karolinska Institutet

慢性腎臓病患者における高カリウム含有の健康的な植物ベース食とカリウム含有量が制限された健康的な植物ベース食の安全性比較:パイロット研究

For many years, people with moderate to advanced chronic kidney disease (CKD) have been advised to limit their intake of potassium, a mineral found in many foods such as fruit, vegetables, legumes, whole grains, and nuts. The reason for this has been the risk of hyperkalemia, a condition in which the potassium level in the blood becomes too high and can be dangerous. In recent years, however, this view has been questioned. New research suggests that the link between potassium in food and high potassium levels in the blood may not be as clear as previously thought. People who follow a strict potassium-restricted diet experience a lower quality of life and less satisfaction with their dietary treatment. At the same time, they miss out on the health benefits of eating a varied and nutritious diet.

Today, many experts advocate a more individualized approach to potassium intake: instead of generally restricting potassium, the goal should be to maintain normal potassium levels in the blood, while encouraging a healthy diet. However, this message is not always clear in healthcare, and many people therefore continue to avoid potassium-rich foods altogether. The result is that they eat fewer natural ingredients and instead consume more processed and ultra-processed foods. Such foods can be more harmful, partly because they often contain potassium additives that are absorbed effectively by the body and their quantities are not reported in the nutritional label. This "hidden" potassium can contribute more to high potassium levels in the blood than the potassium that occurs naturally in plant-based foods. In addition, potassium from whole plant-based foods is absorbed more slowly, partly due to its fiber content.

Plant-based diets may also have other positive effects for people with kidney disease: they can contribute to reduced blood acidity, known as metabolic acidosis, healthier gut flora, lower levels of inflammation, and reduced phosphorus intake. Together, these factors can counteract several of the metabolic complications associated with kidney disease.

In a previous study, our research group showed that even patients with advanced kidney disease (CKD stage 4-5) and already elevated potassium levels could follow a healthy plant-based diet if they also used a potassium-binding drug (sodium zirconium cyclosilicate, SZC). This enabled them to eat more fruit, vegetables, and legumes, while also experiencing improved quality of life. The current study builds on these results and is planned as a pilot study in which patients with moderate to advanced kidney disease, but who are not yet being treated with dialysis, are assigned to two different dietary strategies for six months:

  • Healthy plant-based diet (healthy-PBD): a more liberal and balanced plant-based diet without specific potassium restrictions.
  • Potassium-restricted plant-based diet (restricted-PBD): a traditional plant-based diet with restrictions on potassium-rich foods, according to current standard recommendations.

The main purpose is to investigate whether the healthy plant-based diet leads to more or more severe cases of hyperkalemia than the restricted diet. Our hypothesis is that potassium levels may increase slightly in the group with a liberal diet, but not to dangerous levels. The study will also examine secondary outcomes, such as quality of life, satisfaction with treatment, and how well patients accept the diet. In addition, taste experiences will be tested with taste strips (sweet, sour, salt, bitter and umami) before and after the intervention in both groups. If this pilot study shows that a healthier and less restrictive diet is safe, it could pave the way for a larger study investigating the long-term metabolic effects of a plant-based diet in kidney care.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

The overall aim of the project is to investigate whether a liberal plant-based diet, rich in fruit, vegetables, legumes, whole grains, and nuts, can be recommended to patients with mild to advanced kidney disease without leading to hyperkalemia. Traditionally, dietary advice for chronic kidney disease (CKD) has focused on potassium restriction, which has led to reduced intake of healthy foods and thereby poorer diet quality. This project aims to challenge this view by shifting the focus from potassium content itself to overall diet quality, with a particular focus on patient-centered outcomes such as safety, quality of life, treatment satisfaction, acceptance and sensory effects (taste sensitivity).

The study addresses an important knowledge gap in current nutritional guidelines for patients with kidney disease. The latest recommendations emphasize individualization and maintaining normal potassium levels, rather than general restrictions, but this advice is based on limited evidence and has not yet been tested in longer clinical studies.

This project is therefore limited to conducting a 6-month pilot study with a randomized controlled design. The focus is primarily on safety outcomes, especially the occurrence of hyperkalemia, and secondarily on patient-reported outcomes, dietary acceptance, and taste experience. Metabolic effects are not examined in detail in this study, but the results will form the basis for a larger follow-up study with a broader focus on long-term metabolic and clinical benefits.

The project's main scientific question is whether it is safe for patients with moderate to advanced kidney disease to eat a plant-based diet without restricting potassium-rich foods. In current clinical practice, patients are advised to avoid fruits, vegetables, legumes, and nuts, despite the fact that an increasing number of studies suggest that potassium from whole plant-based foods does not necessarily lead to dangerously high potassium levels in the blood. The study defines the following outcome measures:

Primary outcome: Time to first hyperkalemia event (plasma potassium > 5.5 mmol/L). Number of hyperkalemia events in the two groups during the 22-26 weeks following randomization. Potassium as a continuous variable.

Secondary endpoints: Patient-reported endpoints, quality of life (RAND-36 questionnaire) and satisfaction with treatment. Laboratory markers: inflammation, kidney function, acid-base balance, uremic toxins, vitamin K, and gut flora-related markers. Nutrition-related factors: body composition (measured using bioelectrical impedance), anthropometry, dietary intake, and taste test (sweet, sour, salt, bitter and umami). Dietary compliance: structured questionnaire on intake and 24-hour urine collection for potassium excretion.

This study is designed as a pilot study with a parallel randomized controlled trial (RCT) design with a duration of 22-26 weeks (approximately 6 months). The study will include adult participants (age 20-85) with moderate to advanced CKD, defined as estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m², who are not yet being treated with dialysis nor have undergone kidney transplantation. Individuals with untreated comorbidities or conditions that may affect study participation will be excluded.

Randomization and intervention

Participants will be randomly assigned in a 1:1 ratio to one of two groups:

  • Healthy plant-based diet (healthy-PBD): A liberal plant-based diet that includes fruits, vegetables, legumes, whole grains, and nuts, with no specific restrictions on potassium.
  • Potassium-restricted plant-based diet (restricted-PBD): A plant-based diet with restrictions on potassium-rich foods, which corresponds to current standard advice for patients with CKD.

Both groups will receive individually tailored dietary counselling from a dietitian at baseline and during follow-up visits. Counselling will cover portion sizes, meal composition, and strategies for adhering to the assigned diet. Participants will also receive written dietary advice and food lists.

Study procedures and visits Participants will attend study visits at baseline, 4 weeks, 12 weeks, and 22-26 weeks. The following will be performed at each visit:

  • Blood tests: plasma potassium (primary safety measure), kidney function (creatinine, eGFR), acid-base balance, inflammation markers, vitamin K and uremic toxins.
  • Urine test: 24-hour urine collection for potassium, sodium, urea, and creatinine to assess compliance with the diet.
  • Anthropometry and body composition: weight, body mass index (BMI) and bioelectrical impedance analysis.
  • Patient-reported outcomes: quality of life (RAND-36) and questionnaire on satisfaction with treatment.
  • Sensory tests: taste strips to assess thresholds for sweet, sour, salt, bitter and umami.
  • Diet compliance: structured dietary questionnaire focusing on plant-based foods and potassium-rich foods, as well as a 24-hour record about intake.

Participants are instructed to contact the study team if they experience symptoms that may indicate hyperkalemia, such as muscle weakness or palpitations. If hyperkalemia (p-potassium > 5.5 mmol/L) is detected, adequate medical treatment will be provided, and continued participation in the study will be reconsidered for safety reasons.

Data collection All laboratory analyses will be performed at accredited hospital laboratories according to standardized methods with internal and external quality control. Dietary questionnaires will be validated against urinary potassium excretion. Quality of life and satisfaction questionnaires are validated versions in Swedish. Taste strips will be used under standardized conditions.

To ensure data reliability, all study data will be collected by personnel trained in standardized procedures. Randomization will be computer-generated with concealed allocation. Data entry will be double-checked and deviations verified against source material.

Surveys and interviews The structured dietary surveys will include questions about the frequency and portion size of selected food groups, adherence to prescribed portions, and barriers to following the diet. The survey on treatment satisfaction will include questions about perceived safety, trust in dietary advice, and willingness to continue with the diet after the end of the study. The responses will be analyzed descriptively and compared between groups to identify differences in acceptance and adherence.

Time commitment for participants Each study visit is expected to take approximately 60-90 minutes and will include blood and urine sampling, anthropometry, surveys, and dietary counselling. Participants will also be asked to fill in the dietary records at home and collect 24-hour urine samples at predetermined time points.

The entire study will be conducted in Sweden. All recruitment, intervention, laboratory analyses and follow-up will take place at participating Swedish nephrology clinics.

研究の種類

介入

入学 (推定)

30

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Carla M Avesani, RD, PhD, Associate Professor
  • 電話番号:+46 725460974
  • メール:carla.avesani@ki.se

研究連絡先のバックアップ

研究場所

    • Stockholm Län
      • Huddinge、Stockholm Län、スウェーデン、14152
        • 募集
        • Karolinska Institute
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

20年~85年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria

  • Age between 20 and 85 years
  • Chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m²
  • Normal potassium levels (plasma potassium 3.5-5.3 mmol/L)
  • Not on dialysis
  • Good knowledge of Swedish

Exclusion Criteria

  • Pregnancy
  • Breastfeeding
  • Kidney transplant
  • Regular use of potassium binders at least 4 days/week (e.g. sodium zirconium cyclosilicate, patiromer or sodium polystyrene sulfonate)
  • Regular prescription of daily potassium salts (e.g. potassium chloride)
  • Planned kidney transplant
  • Planned start of dialysis within the next 6 months
  • Allergy to nuts (including peanuts)
  • Mental illness and cognitive impairment that impede understanding of dietary advice
  • Comorbidities that may affect potassium balance (e.g. adrenal insufficiency, inflammatory bowel disease, chronic diarrhoea or colostomy)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:健康的な植物ベースの食事(healthy-PBD)

Healthy plant-based diet (healthy-PBD): A liberal plant-based diet that includes fruits, vegetables, legumes, whole grains, and nuts, with no specific restrictions on potassium.

アクティブコンパレータ:カリウム制限植物性食事法(制限-PBD)

Potassium-restricted plant-based diet (restricted-PBD): A plant-based diet with restrictions on potassium-rich foods, which corresponds to current standard advice for patients with CKD.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of hyperkalemia (plasma potassium >5.5 mmol/L) events in the two groups
時間枠:for 26 weeks following randomization

Hyperkalemia is defined as plasma potassium > 5.5 mmol/L. The number of hyperkalemia events, as well as the time to the event, will be registered.

for 26 weeks following randomization

二次結果の測定

結果測定
メジャーの説明
時間枠
Quality of life (RAND-36 questionnaire - score 0 to 100)
時間枠:for 26 weeks following randomization

Validated for patients with CKD in Sweden - Higher scores reperesent better quality of life

for 26 weeks following randomization
Renal Treatment Satisfaction Questionnaire - score 0 to 6
時間枠:for 26 weeks following randomization

Validated for patients with CKD in Sweden. Comprised of 13 items, each item is scored by the patient from 0 to 6. The higher the score, the higher the satisfaction with the treatment.

for 26 weeks following randomization
C-reactive protein (mg/L)
時間枠:for 26 weeks following randomization

C-reactive protein (mg/L) assessed as a continuous variable

for 26 weeks following randomization
Interleukin 6 (pg/mL)
時間枠:for 26 weeks following randomization

Interleukin 6 (pg/mL) assessed as continous variable

for 26 weeks following randomization
Glomerular filtration rate (ml/min/1.73 m2)
時間枠:for 26 weeks following randomization

Assessed by the Malmö-Lund equation, using serum creatinine (μmmol/L)

for 26 weeks following randomization
Albumin/creatinine ratio (spot urine) (mg/g)
時間枠:for 26 weeks following randomization

Albumin/creatinine ratio (spot urine)

for 26 weeks following randomization
24-hour urinary creatinine excretion (mg/L)
時間枠:for 26 weeks following randomization

24-hour urinary creatinine excretion

for 26 weeks following randomization
Serum creatinine (µmol/L)
時間枠:for 26 weeks following randomization

Serum creatinine (µmol/L)

for 26 weeks following randomization
Plasma carbon dioxide (mmol/L)
時間枠:for 26 weeks following randomization

Plasma carbon dioxide (mmol/L)

for 26 weeks following randomization
Plasma Trimethylamine N-oxide (TMAO) (ng/mL)
時間枠:for 26 weeks following randomization

Trimethylamine N-oxide (TMAO) (ng/mL)

for 26 weeks following randomization
Plasma p-Cresyl sulfate (ng/mL)
時間枠:for 26 weeks following randomization

p-Cresyl sulfate (ng/mL)

for 26 weeks following randomization
Plasma Indoxyl sulfate (ng/mL)
時間枠:for 26 weeks following randomization

Indoxyl sulfate (ng/mL)

for 26 weeks following randomization
Vitamin K
時間枠:for 26 weeks following randomization

dp-ucMGP (pmol/L)

for 26 weeks following randomization
Blood DNA microbial
時間枠:for 26 weeks following randomization

Biomarkers linked to the gut microbiota measured in blood samples

for 26 weeks following randomization
Lean body mass (kg)
時間枠:for 26 weeks following randomization

Assessed by Bioelectrical impedance

for 26 weeks following randomization
Body weight (kg)
時間枠:for 26 weeks following randomization

Assessed with an electronic scale

for 26 weeks following randomization
Potassium intake (mg/day)
時間枠:for 26 weeks following randomization

Assessed by 24 hour food recall

for 26 weeks following randomization
Taste perception of salt (scale 1 to 4)
時間枠:for 26 weeks following randomization

It will be assessed by taste strips (salt). A higher score denotes higher perception.

for 26 weeks following randomization
Dietary compliance
時間枠:for 26 weeks following randomization

Structured questionnaire on intake

for 26 weeks following randomization
24-hour potassium excretion in urine (mmol/day)
時間枠:for 26 weeks following randomization

Will be used to assess dietary compliance to the intake of potassium

for 26 weeks following randomization
Plasma potassium as a continuous variable
時間枠:26 weeks following the randomization

Changes in plasma potassium (mmol/L) will be followed in both groups.

26 weeks following the randomization
Height (cm)
時間枠:26 weeks after the randomization

Assessed with a stadiometer in cm

26 weeks after the randomization
Taste perception of sweet (scale 1 to 4)
時間枠:26 weeks after the randomization

Assessed by taste strips (sweet). A higher score denotes higher perception.

26 weeks after the randomization
Taste perception to sour (scale 1 to 4)
時間枠:26 weeks followed the randomization

Assessed by taste strips (sour). A higher score denotes higher perception.

26 weeks followed the randomization
Taste perception of bitter (scale 1 to 4)
時間枠:26 weeks followed the randomization

Assessed by taste strips (bitter). A higher score denotes higher perception.

26 weeks followed the randomization

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年9月29日

一次修了 (推定)

2029年12月30日

研究の完了 (推定)

2030年6月30日

試験登録日

最初に提出

2026年3月9日

QC基準を満たした最初の提出物

2026年3月20日

最初の投稿 (実際)

2026年3月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月2日

QC基準を満たした最後の更新が送信されました

2026年9月29日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2025-06661-01
  • 2025 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

IPD プランの説明

We can share upon requirement and justification on the purpose for sharing the data.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。